NFXBio: TechBio Platforms Developing a Universal Vaccine & Beating Treatment-Resistant Cancer

In this episode, Nick Goldner and Jacob Glanville share their founder journeys and discuss platform technologies in biotech. They delve into the business models of Resistance Bio and Sentivax, strategies for infectious diseases, and the challenges of scientific entrepreneurship. The conversation shifts to fundraising experiences and understanding investor feedback, concluding with visions for the future of biotech.

Episode metadata supplied by the publisher feed · Published Nov 22, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

NFXBio: TechBio Platforms Developing a Universal Vaccine & Beating Treatment-Resistant Cancer

0:00 51:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The NFX Podcast?

This episode is 51 minutes long.

When was this The NFX Podcast episode published?

This episode was published on November 22, 2022.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this The NFX Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!